Amylyx Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-21$16.92 RISE2026-03-30$12.76 PEAK2026-04-17$18.36 86d | -24.6% 68d | Missed | Missed | — | — | +43.9% 18d | Missed |
DROP2025-10-15$15.79 RISE2026-01-06$11.38 PEAK2026-01-21$16.92 98d | -27.9% 83d | Missed | Missed | — | — | +48.7% 15d | Missed |
DROP2025-10-15$15.79 RISE2025-11-10$12.18 PEAK2026-01-21$16.92 98d | -22.9% 26d | Missed | Missed | — | — | +38.9% 72d | Missed |
DROP2024-11-27$5.74 RISE2025-04-08$3.31 PEAK2025-07-07$6.76 222d | -42.3% 132d | Missed | Missed | — | — | +104.2% 90d | Missed |
DROP2024-11-11$7.03 RISE2025-03-03$3.00 PEAK2025-05-20$5.52 190d | -57.3% 112d | Missed | Missed | — | — | +84.0% 78d | Missed |
DROP2024-11-11$7.03 RISE2025-02-24$3.00 PEAK2025-05-20$5.52 190d | -57.3% 105d | Missed | Missed | — | — | +84.0% 85d | Missed |
DROP2024-11-11$7.03 RISE2025-01-14$3.13 PEAK2025-03-12$3.91 121d | -55.5% 64d | Missed | Missed | — | — | +24.9% 57d | Missed |
DROP2024-04-01$2.71 RISE2024-08-08$1.80 PEAK2024-11-01$5.64 214d | -33.6% 129d | Missed | Missed | — | — | +213.3% 85d | Missed |
DROP2024-02-28$19.57 RISE2024-06-18$1.62 PEAK2024-09-10$2.66 195d | -91.7% 111d | Missed | Missed | — | — | +64.2% 84d | Missed |
DROP2023-07-31$23.45 RISE2023-11-17$12.07 PEAK2024-01-08$16.87 161d | -48.5% 109d | Missed | Missed | — | — | +39.8% 52d | Missed |
DROP2023-03-08$36.10 RISE2023-07-07$20.37 PEAK2023-07-31$23.45 145d | -43.6% 121d | Missed | Missed | — | — | +15.1% 24d | Missed |
DROP2022-12-01$39.26 RISE2022-12-19$33.28 PEAK2023-01-27$40.93 57d | -15.2% 18d | Missed | Missed | — | — | +23.0% 39d | Missed |
DROP2022-07-29$26.99 RISE2022-09-06$17.15 PEAK2022-11-25$38.75 119d | -36.5% 39d | Missed | Missed | — | — | +125.9% 80d | Missed |
DROP2022-02-28$32.90 RISE2022-05-11$6.85 PEAK2022-07-29$26.99 151d | -79.2% 72d | Missed | Missed | — | — | +294.0% 79d | Missed |
Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is among the best pharmaceutical stocks. TheFly reported on May 7 that AMLX reported first-quarter 2026 results for the period ended March 31, 2026, alongside pipeline and clinical updates. R&D expenses rose to $27.6 […]
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of
Peer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple...
Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the third quarter, Co-Chief Executive Officer Joshua Cohen said at the BofA Annual Healthcare Conferenc
Amylyx Pharmaceuticals, Inc. (AMLX) Bank of America Global Healthcare Conference 2026 May 13, 2026 4:40 PM EDTCompany ParticipantsJoshua Cohen - Co-Founder,...
FDA drug approvals are reshaping biotech stocksâtrack key decisions, FDA leadership turmoil, and volatility. Click for a look at the issues surrounding the FDA.
Justin Klee: Good morning, everyone, and thank you for joining us. Most notably, we continue to progress the pivotal Phase III LUCIDITY trial of avexitide, our investigational first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation in post-bariatric hypoglycemia or PBH. First, we are advancing the pivotal Phase III LUCIDITY trial toward top line data.
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDTCompany ParticipantsLindsey Allen - Head of Investor Relations &...
Presentation Operator MessageOperator Good morning. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First...
Amylyx Pharmaceuticals (NASDAQ:AMLX) executives highlighted continued progress across the company’s pipeline during its first-quarter 2026 earnings call, with a heavy focus on the pivotal Phase 3 LUCIDITY trial evaluating avexitide in post-bariatric hypoglycemia (PBH) and preparations for a potentia
Amylyx Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 41.28 million compared to USD 35.91...
Amylyx Pharmaceuticals Q1 2026 net loss slightly beats estimates as focus shifts to pivotal Phase 3 avexitide trial results for PBH, expected Q3 2026.
Topline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026Cash runway expected to fund operations through potential...
Amylyx Pharmaceuticals, Inc. today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person:Bank of America’s 2026 Health...
CAMBRIDGE, Mass., May 05, 2026--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment access to avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AMLX | -10.37% | -6.21% | +18.79% | +178.64% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -13.34% | -0.49% | +22.23% | +165.95% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 16.63M | $231.16M | 0.01% | Added+0.7% | 2026-03-31 |
| StateStreet | passive | 2.36M | $32.85M | 0.00% | Added+14.2% | 2026-03-31 |
| Wellington | fundamental | 241.6K | $3.36M | 0.00% | Added+7.0% | 2026-03-31 |
| TwoSigma | quant | 161.9K | $2.25M | 0.00% | Trimmed-53.0% | 2026-03-31 |
| Citadel | multi-strat | 106.5K | $1.48M | 0.00% | Trimmed-68.2% | 2026-03-31 |
| DEShaw | quant | 74.2K | $1.03M | 0.00% | Added+1.4% | 2026-03-31 |
| TRowePrice | fundamental | 121.4K | $1.69K | 0.00% | Added+12.9% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.35 | — | — |
| 2026-05-07 | -0.34 | -0.37 | -8.71% |
| 2026-03-03 | -0.34 | -0.30 | +12.23% |
| 2025-11-06 | -0.43 | -0.37 | +13.93% |
| 2025-08-07 | -0.45 | -0.46 | -1.23% |
| 2025-05-08 | -0.50 | -0.42 | +16.00% |
| 2025-03-04 | -0.52 | -0.55 | -5.77% |
| 2024-11-07 | -0.56 | -1.07 | -89.38% |
| 2024-08-08 | -0.82 | -0.62 | +23.91% |
| 2024-05-09 | -0.01 | -0.12 | -1946.50% |
| 2024-02-22 | 0.23 | 0.07 | -69.27% |
| 2023-11-09 | 0.44 | 0.30 | -31.30% |
| 2023-08-10 | 0.07 | 0.31 | +342.86% |
| 2023-05-11 | -0.25 | 0.02 | +108.11% |
| 2023-03-13 | -0.84 | -0.65 | +22.77% |
| 2022-11-10 | -0.98 | -0.92 | +5.69% |